동물용 백신 시장 분석 및 예측(-2035년) : 유형, 제품 유형, 기술, 용도, 최종 사용자, 형태, 컴포넌트, 단계, 설치 유형

Animal Health Vaccines Market is anticipated to expand from $13.2 billion in 2024 to $33.1 billion by 2034, growing at a CAGR of approximately 9.8%. The Animal Health Vaccines Market encompasses the development and distribution of immunizations designed to prevent diseases in livestock, companion animals, and aquaculture. This market is driven by the increasing prevalence of zoonotic diseases, advancements in vaccine technology, and rising awareness of animal welfare. Growth is supported by innovations in recombinant and live attenuated vaccines, alongside regulatory initiatives promoting animal health. Demand is further bolstered by the expansion of livestock production and the pet care industry, emphasizing the critical role of vaccines in safeguarding animal and public health.

The Animal Health Vaccines Market is experiencing robust growth, fueled by advancements in biotechnology and increasing awareness of animal health. The livestock vaccines segment is the top performer, driven by the necessity to prevent diseases in cattle, poultry, and swine. Within this segment, the poultry vaccines sub-segment shows remarkable growth due to the high demand for disease prevention in large-scale poultry operations. The companion animal vaccines segment emerges as the second highest performer, reflecting the rising trend of pet ownership and the consequent demand for preventive healthcare. In this segment, canine vaccines are particularly prominent, as they address common health concerns in dogs, such as rabies and distemper. The equine vaccines sub-segment also shows potential, driven by the increasing value placed on equine health and performance. Innovations in vaccine delivery methods, such as oral and intranasal vaccines, are gaining attention, offering improved convenience and compliance. The market is poised for continued expansion as stakeholders invest in research and development to enhance vaccine efficacy and coverage.

Market Snapshot:

The animal health vaccines market is characterized by a dynamic landscape where market share is distributed among established and emerging players. Pricing strategies are diverse, reflecting the competitive nature of the industry and the pursuit of market penetration. New product launches are frequent, driven by advancements in biotechnology and the increasing demand for effective disease prevention solutions. Companies are focusing on innovation to cater to a wide range of animal species, enhancing their portfolios to meet the evolving needs of veterinary healthcare. Competition benchmarking reveals a market dominated by a few key players, with smaller firms striving to carve out niche segments. Regulatory influences are significant, with stringent guidelines shaping product development and market entry. Compliance with international standards is crucial for market success, impacting both pricing and competitive positioning. The market is poised for growth, with increasing awareness of animal health and welfare driving demand. Technological integration and regulatory harmonization present both challenges and opportunities for stakeholders.

Geographical Overview:

The Animal Health Vaccines Market is witnessing substantial growth across various regions, each presenting unique opportunities. North America leads due to advanced veterinary healthcare infrastructure and increasing pet ownership. The region's focus on preventive animal healthcare and rising livestock production further propels market growth. Europe follows, driven by stringent regulations on animal health and welfare, which encourage vaccine adoption. Asia Pacific is emerging as a lucrative market, fueled by rising awareness about animal health and increasing livestock population. Countries like China and India are at the forefront, investing heavily in veterinary healthcare advancements. The region's expanding middle class and growing pet adoption rates further enhance market potential. Latin America and the Middle East & Africa are also gaining traction. In Latin America, the demand for livestock vaccines is rising, while the Middle East & Africa are recognizing the importance of animal health in ensuring food security and economic development.

Key Trends and Drivers:

The Animal Health Vaccines Market is experiencing robust growth fueled by rising pet ownership and livestock production. Increased awareness of zoonotic diseases is driving demand for effective vaccination solutions. Technological advancements in vaccine development, such as recombinant DNA technology, are enhancing vaccine efficacy and safety. Key trends include the shift towards subunit and DNA vaccines, which offer targeted immune responses and reduced side effects. Furthermore, regulatory support for animal health initiatives is fostering innovation and market expansion. The growing emphasis on animal welfare and preventive healthcare is encouraging vaccine adoption. Drivers include the need to mitigate disease outbreaks that can impact food security and public health. The expansion of veterinary services in emerging markets is also contributing to market growth. Opportunities abound in developing regions where livestock farming is integral to the economy. Companies that focus on affordable, scalable vaccine solutions are positioned to capture significant market share. The integration of digital technologies for vaccine tracking and management is another promising avenue for growth.

Restraints and Challenges:

The animal health vaccines market is confronted with several significant restraints and challenges. A primary challenge is the stringent regulatory environment, which prolongs the approval process for new vaccines. This delay can hinder timely market entry and increase costs for manufacturers. Additionally, the high costs associated with vaccine development and production can be prohibitive, particularly for smaller companies. Another challenge is the complexity of emerging diseases, which necessitates continuous research and adaptation of vaccines. This can strain resources and require substantial investment. Furthermore, there is a lack of awareness and education among livestock owners about the benefits of vaccination, leading to lower adoption rates. In certain regions, inadequate infrastructure and distribution networks pose logistical challenges, limiting vaccine accessibility. Lastly, the market faces competition from alternative animal health solutions, such as antibiotics and nutritional supplements, which can reduce reliance on vaccines. These factors collectively impede the growth and expansion of the animal health vaccines market.

Key Players:

Virbac, Ceva Sante Animale, Hipra, Biogenesis Bago, Phibro Animal Health, Indian Immunologicals, Hester Biosciences, Vaxxinova, Biovac, Merial, IDT Biologika, Laboratorios Laverlam, Nisseiken, Bioveta, Merial

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Technology
• 2.4 Key Market Highlights by Application
• 2.5 Key Market Highlights by End User
• 2.6 Key Market Highlights by Form
• 2.7 Key Market Highlights by Component
• 2.8 Key Market Highlights by Stage
• 2.9 Key Market Highlights by Installation Type

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Attenuated Vaccines
  • 4.1.2 Inactivated Vaccines
  • 4.1.3 Subunit Vaccines
  • 4.1.4 Conjugate Vaccines
  • 4.1.5 Toxoid Vaccines
  • 4.1.6 DNA Vaccines
  • 4.1.7 Recombinant Vaccines
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Livestock Vaccines
  • 4.2.2 Companion Animal Vaccines
  • 4.2.3 Aquaculture Vaccines
  • 4.2.4 Poultry Vaccines
  • 4.2.5 Porcine Vaccines
  • 4.2.6 Equine Vaccines
• 4.3 Market Size & Forecast by Technology (2020-2035)
  • 4.3.1 Live Attenuation
  • 4.3.2 Inactivation
  • 4.3.3 Recombinant DNA
  • 4.3.4 Toxoid
• 4.4 Market Size & Forecast by Application (2020-2035)
  • 4.4.1 Disease Prevention
  • 4.4.2 Therapeutic Treatment
  • 4.4.3 Diagnostic Applications
• 4.5 Market Size & Forecast by End User (2020-2035)
  • 4.5.1 Veterinary Clinics
  • 4.5.2 Animal Farms
  • 4.5.3 Research Institutes
• 4.6 Market Size & Forecast by Form (2020-2035)
  • 4.6.1 Liquid
  • 4.6.2 Lyophilized
• 4.7 Market Size & Forecast by Component (2020-2035)
  • 4.7.1 Antigen
  • 4.7.2 Adjuvant
  • 4.7.3 Stabilizers
  • 4.7.4 Preservatives
• 4.8 Market Size & Forecast by Stage (2020-2035)
  • 4.8.1 Research and Development
  • 4.8.2 Clinical Trials
  • 4.8.3 Commercialization
• 4.9 Market Size & Forecast by Installation Type (2020-2035)
  • 4.9.1 On-Site
  • 4.9.2 Off-Site

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Technology
    • 5.2.1.4 Application
    • 5.2.1.5 End User
    • 5.2.1.6 Form
    • 5.2.1.7 Component
    • 5.2.1.8 Stage
    • 5.2.1.9 Installation Type
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Technology
    • 5.2.2.4 Application
    • 5.2.2.5 End User
    • 5.2.2.6 Form
    • 5.2.2.7 Component
    • 5.2.2.8 Stage
    • 5.2.2.9 Installation Type
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Technology
    • 5.2.3.4 Application
    • 5.2.3.5 End User
    • 5.2.3.6 Form
    • 5.2.3.7 Component
    • 5.2.3.8 Stage
    • 5.2.3.9 Installation Type
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Technology
    • 5.3.1.4 Application
    • 5.3.1.5 End User
    • 5.3.1.6 Form
    • 5.3.1.7 Component
    • 5.3.1.8 Stage
    • 5.3.1.9 Installation Type
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Technology
    • 5.3.2.4 Application
    • 5.3.2.5 End User
    • 5.3.2.6 Form
    • 5.3.2.7 Component
    • 5.3.2.8 Stage
    • 5.3.2.9 Installation Type
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Technology
    • 5.3.3.4 Application
    • 5.3.3.5 End User
    • 5.3.3.6 Form
    • 5.3.3.7 Component
    • 5.3.3.8 Stage
    • 5.3.3.9 Installation Type
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Technology
    • 5.4.1.4 Application
    • 5.4.1.5 End User
    • 5.4.1.6 Form
    • 5.4.1.7 Component
    • 5.4.1.8 Stage
    • 5.4.1.9 Installation Type
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Technology
    • 5.4.2.4 Application
    • 5.4.2.5 End User
    • 5.4.2.6 Form
    • 5.4.2.7 Component
    • 5.4.2.8 Stage
    • 5.4.2.9 Installation Type
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Technology
    • 5.4.3.4 Application
    • 5.4.3.5 End User
    • 5.4.3.6 Form
    • 5.4.3.7 Component
    • 5.4.3.8 Stage
    • 5.4.3.9 Installation Type
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Technology
    • 5.4.4.4 Application
    • 5.4.4.5 End User
    • 5.4.4.6 Form
    • 5.4.4.7 Component
    • 5.4.4.8 Stage
    • 5.4.4.9 Installation Type
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Technology
    • 5.4.5.4 Application
    • 5.4.5.5 End User
    • 5.4.5.6 Form
    • 5.4.5.7 Component
    • 5.4.5.8 Stage
    • 5.4.5.9 Installation Type
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Technology
    • 5.4.6.4 Application
    • 5.4.6.5 End User
    • 5.4.6.6 Form
    • 5.4.6.7 Component
    • 5.4.6.8 Stage
    • 5.4.6.9 Installation Type
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Technology
    • 5.4.7.4 Application
    • 5.4.7.5 End User
    • 5.4.7.6 Form
    • 5.4.7.7 Component
    • 5.4.7.8 Stage
    • 5.4.7.9 Installation Type
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Technology
    • 5.5.1.4 Application
    • 5.5.1.5 End User
    • 5.5.1.6 Form
    • 5.5.1.7 Component
    • 5.5.1.8 Stage
    • 5.5.1.9 Installation Type
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Technology
    • 5.5.2.4 Application
    • 5.5.2.5 End User
    • 5.5.2.6 Form
    • 5.5.2.7 Component
    • 5.5.2.8 Stage
    • 5.5.2.9 Installation Type
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Technology
    • 5.5.3.4 Application
    • 5.5.3.5 End User
    • 5.5.3.6 Form
    • 5.5.3.7 Component
    • 5.5.3.8 Stage
    • 5.5.3.9 Installation Type
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Technology
    • 5.5.4.4 Application
    • 5.5.4.5 End User
    • 5.5.4.6 Form
    • 5.5.4.7 Component
    • 5.5.4.8 Stage
    • 5.5.4.9 Installation Type
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Technology
    • 5.5.5.4 Application
    • 5.5.5.5 End User
    • 5.5.5.6 Form
    • 5.5.5.7 Component
    • 5.5.5.8 Stage
    • 5.5.5.9 Installation Type
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Technology
    • 5.5.6.4 Application
    • 5.5.6.5 End User
    • 5.5.6.6 Form
    • 5.5.6.7 Component
    • 5.5.6.8 Stage
    • 5.5.6.9 Installation Type
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Technology
    • 5.6.1.4 Application
    • 5.6.1.5 End User
    • 5.6.1.6 Form
    • 5.6.1.7 Component
    • 5.6.1.8 Stage
    • 5.6.1.9 Installation Type
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Technology
    • 5.6.2.4 Application
    • 5.6.2.5 End User
    • 5.6.2.6 Form
    • 5.6.2.7 Component
    • 5.6.2.8 Stage
    • 5.6.2.9 Installation Type
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Technology
    • 5.6.3.4 Application
    • 5.6.3.5 End User
    • 5.6.3.6 Form
    • 5.6.3.7 Component
    • 5.6.3.8 Stage
    • 5.6.3.9 Installation Type
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Technology
    • 5.6.4.4 Application
    • 5.6.4.5 End User
    • 5.6.4.6 Form
    • 5.6.4.7 Component
    • 5.6.4.8 Stage
    • 5.6.4.9 Installation Type
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Technology
    • 5.6.5.4 Application
    • 5.6.5.5 End User
    • 5.6.5.6 Form
    • 5.6.5.7 Component
    • 5.6.5.8 Stage
    • 5.6.5.9 Installation Type

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Virbac
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Ceva Sante Animale
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Hipra
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Biogenesis Bago
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Phibro Animal Health
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Indian Immunologicals
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Hester Biosciences
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Vaxxinova
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Biovac
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Merial
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 IDT Biologika
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Laboratorios Laverlam
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Nisseiken
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Bioveta
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Merial
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us